J.P Morgan 42nd Annual Healthcare Conference

🌐Sound Bioventures will be in San Francisco between the 8-11 January attending the J.P Morgan 42nd Annual Healthcare Conference. This event, and the many other events and receptions that week, offer the opportunity to connect with our portfolio companies, our peers and colleagues within the investment community and a wide spectrum of leading biopharma and biotech companies.

Two of our managing partners, Johan Kördel and Bibash Mukhopadhyay, will be in San Francisco representing Sound Bioventures. If you would like to meet with Johan and Bibash, please get in touch at info@soundbioventures.com.

Sound Bioventures is a specialist life sciences venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing therapeutics in areas of significant clinical unmet need.

Visit https://soundbioventures.com/ to learn more about our company, investment approach and current portfolio.

#SoundBioventures #JPM24 #lifesciences

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

June 20, 2024 Seattle, WA – NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures. together with a previously announced strategic corporate partnership, the capital will be used to advance NDI-5001, a proprietary small mole ...


* indicates required